EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1069-1069 ◽  
Author(s):  
Hope S. Rugo ◽  
Johannes Ettl ◽  
Natasha E. Woodward ◽  
Sara A. Hurvitz ◽  
Anthony Goncalves ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Brca Mutation ◽  
Parp Inhibitor ◽  
Advanced Breast ◽  
Germline Brca Mutation ◽  
Choice Of Therapy

scholarly journals A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)

2015 ◽  
Vol 26 ◽  
pp. ii16 ◽  
Author(s):  
H. Roche ◽  
J. Blum ◽  
W. Eiermann ◽  
Y.-H. Im ◽  
M. Martin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Brca Mutation ◽  
Parp Inhibitor ◽  
Advanced Breast ◽  
Phase 3

scholarly journals Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 ◽  
Vol 379 (8) ◽  
pp. 753-763 ◽  
Author(s):  
Jennifer K. Litton ◽  
Hope S. Rugo ◽  
Johannes Ettl ◽  
Sara A. Hurvitz ◽  
Anthony Gonçalves ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Brca Mutation ◽  
Advanced Breast ◽  
Germline Brca Mutation

Olaparib for advanced breast cancer

2020 ◽  
Vol 16 (12) ◽  
pp. 717-732 ◽  
Author(s):  
Gaia Griguolo ◽  
Maria Vittoria Dieci ◽  
Federica Miglietta ◽  
Valentina Guarneri ◽  
PierFranco Conte
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Parp Inhibitor ◽  
Progression Free Survival ◽  
Advanced Breast ◽  
Phase Iii ◽  
Breast Cancer Patients ◽  
Open Questions ◽  
Overall Survival Benefit

Olaparib, an oral PARP-inhibitor, has shown clinical benefit for HER2-negative advanced breast cancer patients carrying a germinal BRCA1/2 mutation. In a randomized Phase III trial, olaparib significantly prolonged progression-free survival as compared with chemotherapy of physician choice. Moreover, in the same trial, a prespecified subgroup analysis reported an overall survival benefit for patients not previously pretreated with chemotherapy for metastatic disease. This review focuses on available preclinical, pharmacokinetic and pharmacodynamic data regarding olaparib and clinical evidence of its antitumor efficacy (both as monotherapy and in combination) and tolerability in breast cancer patients. Open questions, such as use of appropriate biomarkers for patient selection and combination/sequencing with other anticancer drugs, are also addressed.

Sign in / Sign up

Export Citation Format

Share Document